Navigation Links
Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents

SAN FRANCISCO, Oct. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2007 AACR-NCI- EORTC International Conference in San Francisco that its integrin-targeted PI3 kinase inhibitor, SF1126, showed synergistic effects with certain standard chemotherapy agents in vitro and in vivo (poster C207).

In vitro data showed significant (p<0.001) synergistic growth inhibition of prostate cancer cells with combinations of docetaxel and SF1126, as well as synergistic growth inhibition of brain cancer cells with combinations of doxorubicin and SF1126. In addition, SF1126 and rapamycin showed excellent growth inhibition synergies across all prostate, renal and non-small cell lung cancer cell lines. Simultaneous dosing of SF1126 with docetaxel in a prostate xenograft model exhibited slightly improved tumor response time versus administering SF1126 prior to docetaxel administration. In this same xenograft model, using very large tumors, it was shown that SF1126 in combination with docetaxel gave significantly greater tumor regression than did docetaxel alone (p<0.05). SF1126 as a single agent showed significant tumor growth inhibition relative to the control group (73% inhibition, p<0.01) in this model as well.

"These data support that our lead compound, SF1126, is active as a single agent and in synergy with a growing list of standard chemotherapy agents," said Edward Jacobs, Semafore's president and chief executive officer. "This provides us with a pathway to clinical development in addition to our current phase I clinical trial in patients with solid tumors. We expect to complete our phase I clinical trial in the second quarter of 2008 and then evaluate SF1126 in additional trials, both as a single and combined therapy."

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway, via SF1126, could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus--cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PENN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets. For more information see the company's website at

Contact: David Schull or Timothy Engel

Russo Partners, LLC


SOURCE Semafore Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
5. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
9. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
10. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
11. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
(Date:11/26/2015)... 2015 ) has ... of High Viscosity Drugs" report to their ... the addition of the "Self Administration of ... --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" report ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... Consultants has prided itself for not only fulfilling the needs of advisers and ... at an affordable price and providing top-tier customer service. However, there's always room ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... They observed that both STEMI and Sepsis conditions present in similar ways and require ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into ... Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that ...
(Date:11/26/2015)... NV (PRWEB) , ... November 26, 2015 , ... Inevitably ... strategy. Many customers choose to buy during the Black Friday and Cyber Monday ... Shoppers don’t need to search the Internet high and low to find the best ...
Breaking Medicine News(10 mins):